U.S. Water Utilities Stock News

NasdaqGS:REYN
NasdaqGS:REYNHousehold Products

Is Reynolds Consumer Products (REYN) Still Attractive After Recent Share Price Stability

Investors may be wondering if Reynolds Consumer Products, at around US$24.28 a share, still offers solid value or if most of the opportunity is already reflected in the price. Over the short term, the stock has been fairly steady, with a 0.2% decline over 7 days, a 3.1% gain over 30 days, and a 5.3% return year to date. The 1 year return sits at an 8.7% decline, and the 3 and 5 year returns are 8.2% and 8.9% declines respectively. Recent attention on household and consumer staples companies...
NYSE:MUR
NYSE:MUROil and Gas

Murphy Oil Reassesses Côte D'Ivoire After Civette Setback And New Prospects

Murphy Oil (NYSE:MUR) reported that its Civette-1X exploration well offshore Côte d'Ivoire encountered non-commercial hydrocarbons. The result, in Block CI-502, was announced as an early-stage outcome that will inform the company's international exploration efforts. Murphy Oil plans to focus next on the nearby Caracal and Bubale prospects in the same offshore area. Murphy Oil, an independent exploration and production company, is using this early result from Civette-1X as a data point for...
NYSE:SFBS
NYSE:SFBSBanks

ServisFirst Bancshares Q4 Net Interest Margin Strengthens Bullish Narratives On Profitability

ServisFirst Bancshares (SFBS) capped FY 2025 with fourth quarter revenue of US$154.3 million and EPS of US$1.58, as trailing twelve month figures reached US$527.1 million in revenue and EPS of US$5.06. Over the past year, revenue has moved from US$458.7 million on a trailing basis to US$527.1 million, while EPS over the same period shifted from US$4.17 to US$5.06, providing additional context for how you might think about the bank’s earnings power. With a trailing net profit margin of 52.5%...
NYSE:SCHW
NYSE:SCHWCapital Markets

Schwab (SCHW) Margin Expansion Reinforces Bullish Narratives Despite Modest Revenue Growth

Charles Schwab FY 2025 Earnings Snapshot Charles Schwab (SCHW) closed FY 2025 with fourth quarter revenue of US$6.3 billion and basic EPS of US$1.34, alongside net income excluding extra items of US$2.4 billion, putting a solid set of headline numbers in front of investors. The company has seen quarterly revenue move from US$5.3 billion and EPS of US$0.94 in Q4 2024 to US$6.3 billion and EPS of US$1.34 in Q4 2025, alongside trailing twelve month EPS of US$4.67 and revenue of US$24.0 billion...
NasdaqGM:ATRC
NasdaqGM:ATRCMedical Equipment

AtriCure (ATRC) Is Up 5.1% After Raising 2026 Guidance And Refinancing Credit Facility - Has The Bull Case Changed?

Earlier in January 2026, AtriCure issued 2026 revenue guidance of approximately US$600 million to US$610 million and amended its asset-based revolving credit facility, extending the term, lowering interest rates and maintaining up to US$125 million in borrowing capacity with the option to increase to US$165 million. Together, the higher revenue outlook and more flexible, lower-cost credit line highlight management’s confidence in AtriCure’s growth plans and liquidity position. Next, we’ll...
NasdaqGS:UAL
NasdaqGS:UALAirlines

United Airlines Holdings UAL Q4 EPS Beat Tests Bearish Margin Concerns

United Airlines FY 2025 Earnings Snapshot United Airlines Holdings (UAL) has wrapped up FY 2025 with Q4 revenue of US$15.4b and basic EPS of US$3.19, supported by net income of US$1,044m. Over recent quarters, the company has seen revenue move from US$14.7b in Q4 2024 to US$15.2b in Q3 2025 and US$15.4b in Q4 2025. Basic EPS over the same Q4 periods shifted from US$2.94 to US$3.19, setting up a results season where investors can weigh steady top line and earnings against how efficiently those...
NasdaqGS:DAWN
NasdaqGS:DAWNBiotechs

Assessing Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Growth Outlook

Why Day One Biopharmaceuticals is in the spotlight Day One Biopharmaceuticals (DAWN) is back on investors’ radar after releasing preliminary 2025 OJEMDA revenue figures and issuing fresh 2026 guidance that ties directly to prescription and patient demand trends. The company reported unaudited OJEMDA net product revenue of approximately US$52.8 million for the fourth quarter of 2025 and US$155.4 million for the full year, with prescription volumes reaching 1,394 in the quarter. Management also...
NasdaqGS:FCFS
NasdaqGS:FCFSConsumer Finance

Latin America Expansion Push Could Be A Game Changer For FirstCash Holdings (FCFS)

FirstCash Holdings recently reported a quarterly update highlighting solid pawn demand, steady merchandise margins, and expanding consumer lending operations across Mexico and broader Latin America. A key insight from the update is management’s continued focus on disciplined growth through new store openings and selective acquisitions in Latin American markets. With this backdrop and growing emphasis on Latin American expansion, we’ll now examine how these developments shape FirstCash...
NYSE:ST
NYSE:STElectrical

Should Sensata’s New STEV High‑Voltage Contactors Reshape the EV Narrative for Sensata Technologies (ST) Investors?

In mid-January 2026, Sensata Technologies announced the launch of its STEV high-voltage contactor series, a scalable, customizable solution designed to improve safety, efficiency and integration across battery electric and plug-in hybrid vehicle platforms from passenger cars to heavy-duty trucks. A distinctive aspect of the STEV lineup is its combination of bidirectional current capability, hermetic ceramic sealing and global in-region manufacturing, positioning Sensata as a key enabler of...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

Is Voyager Technologies (VOYG) Pricing Reflect Its Recent Volatility And Conflicting Valuation Signals

If you are trying to figure out whether Voyager Technologies at US$32.39 is priced attractively or not, you are in the right place. The stock has had a mixed recent run, with a 14.2% gain over the last 30 days but a 5.7% decline over the last week, which can change how investors think about both opportunity and risk. Recent coverage around Voyager Technologies has focused on how the stock fits into the capital goods sector and where it might sit on investors' watchlists. This has given more...
NYSE:TDY
NYSE:TDYElectronic

Teledyne Technologies Q4 EPS Strength Tests Slower Growth Narratives

Teledyne Technologies (TDY) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$5.60, alongside trailing twelve month revenue of US$6.1b and EPS of US$18.88 that frame the latest print in a broader earnings run. Over the past six quarters in the data, quarterly revenue has ranged from US$1.44b to US$1.61b, while basic EPS has moved between US$4.03 and US$5.61, giving investors a clear view of how the top and bottom lines have tracked together through recent...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

How Corsair’s AI-Enabled Peripheral Ecosystem Push Will Impact Corsair Gaming (CRSR) Investors

Corsair Gaming recently used CES 2026 to showcase an expanded ecosystem that connects high-performance gaming hardware, Stream Deck workflows, and early support for Model Context Protocol to enable natural language and voice interactions with AI agents. An especially interesting highlight was the GALLEON 100 SD, a CES Innovation Award-winning keyboard that fuses mechanical gaming performance with integrated Stream Deck controls, signaling Corsair’s push to make AI-enabled, multi-function...
NYSE:UTI
NYSE:UTIConsumer Services

Is It Too Late To Consider Universal Technical Institute (UTI) After Strong Multi‑Year Share Gains?

If you are wondering whether Universal Technical Institute's share price still offers value after recent moves, it helps to step back and look at what the current market price might be implying. The stock last closed at US$28.15, with returns of 5.9% over the past week, 5.0% over the last month, 13.3% year to date, 6.1% over 1 year, and very large gains over 3 and 5 years. Recent attention on Universal Technical Institute has focused on its role in career and technical education, as...
NYSE:PAG
NYSE:PAGSpecialty Retail

How Investors May Respond To Penske Automotive Group (PAG) Analyst Upgrade Amid Shifting Earnings Expectations

Penske Automotive Group was recently upgraded to a Zacks Rank #2 (Buy), reflecting a shift toward more favorable earnings estimate revisions by covering analysts. This upgrade comes against a backdrop of mixed operating trends, including prior concerns over same-store sales and margin pressure, highlighting how analyst sentiment can pivot as expectations evolve. Against this backdrop of improving earnings estimates, we’ll explore how the analyst upgrade influences Penske Automotive Group’s...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

How Record Q3 Results And FDA-Cleared MRI Pump Launch At IRADIMED (IRMD) Has Changed Its Investment Story

Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025. Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress

Why VK2735’s latest trial results matter for Viking Therapeutics (VKTX) Viking Therapeutics (VKTX) is back in focus after publishing Phase 2 VENTURE trial results for its dual GLP-1/GIP candidate VK2735 and confirming full enrollment in two large Phase 3 obesity and diabetes studies. See our latest analysis for Viking Therapeutics. VKTX’s share price has been choppy around the latest VK2735 updates, with a 7 day share price return of 4.71% but a 30 day share price return of 8.32% and a year...
NasdaqGS:UPBD
NasdaqGS:UPBDSpecialty Retail

Is Upbound Group (UPBD) Pricing Reflect Recent Volatility In Rent To Own Retail?

If you are wondering whether Upbound Group's current share price reflects its underlying value, you are not alone. This article focuses squarely on what the numbers say about the stock. The share price closed at US$19.43, with a 9.7% gain over the last 30 days but a 29.4% decline over the past year. This raises questions about how the market is currently pricing the business and its risks. Recent news flow for Upbound Group has included ongoing commentary around the rent to own and lease to...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial

AbCellera Biologics (ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for menopausal vasomotor symptoms. See our latest analysis for AbCellera Biologics. The ABCL635 Phase 2 start comes as AbCellera’s 30 day share price return of 15.05% and year to date share price return of 24.78% contrast with a 3 year total shareholder return of 58.89% decline, suggesting sentiment has improved recently after a...
NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

Is It Time To Reassess Newmark Group (NMRK) After Its Strong Three Year Share Price Run

If you are wondering whether Newmark Group's share price still offers value after a long run on the market, this article breaks down what the current valuation implies for you as a shareholder or potential investor. Newmark Group's stock last closed at US$17.75, with returns of 5.7% over 7 days, 1.5% over 30 days, 4.6% year to date, 30.1% over 1 year and 113.0% over 3 years. These figures raise fair questions about how much of the story is already reflected in the price. Recent coverage has...
NYSE:RBA
NYSE:RBACommercial Services

RB Global Upgrade Highlights International Growth And Valuation Upside Potential

National Bank Financial recently upgraded RB Global (NYSE:RBA), highlighting market share gains and contract wins in Australia and the UK. The firm pointed to new agreements with Suncorp and Direct Line as key drivers of RB Global's expanding presence in vehicle and asset remarketing. The upgrade focuses on the company's growing international footprint and its potential to win additional business in core markets. RB Global runs auctions and related services that help businesses sell heavy...
NasdaqGS:CBSH
NasdaqGS:CBSHBanks

Commerce Bancshares Expands Wealth Focus With FineMark Acquisition Completion

Commerce Bancshares (NasdaqGS:CBSH) has closed its acquisition of FineMark National Bank & Trust. The deal expands Commerce's wealth management and private banking reach into Florida, Arizona, and South Carolina. FineMark will operate as a division within Commerce Bank while maintaining existing client relationships. For investors, this move adds more scale and breadth to Commerce Bancshares' long standing banking and wealth management franchise. Wealth management and private banking have...
NasdaqGM:FOLD
NasdaqGM:FOLDBiotechs

A Look At Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum

Event context and recent stock performance Amicus Therapeutics (FOLD) has caught investor attention after a sharp share price move in the past 3 months, with the stock returning about 69% over that period. See our latest analysis for Amicus Therapeutics. That sharp 68.82% 90 day share price return sits alongside a 50.42% 1 year total shareholder return, while the 5 year total shareholder return of a 24.39% decline shows longer term holders have had a tougher journey, which suggests that...
NYSE:QSR
NYSE:QSRHospitality

Is Restaurant Brands International (QSR) Offering Value After Recent Share Price Softness?

If you are wondering whether Restaurant Brands International is fairly priced or offering value right now, it helps to start by looking at how the market has treated the stock recently and how that lines up with the underlying business. The share price recently closed at US$68.02, with a 7 day return of a 2.7% decline, a 30 day return of a 3.3% decline, a 1 year return of 16.6% and a 5 year return of 41.6%. This gives you a mixed picture of shorter term softness alongside longer term...